First Scientific Description of the Hepato-Lenticular Degeneration
Objective: Hepato-Lenticular Degeneration (HLD) first described by German pathologist Friedrich Theodor von Frerichs in 1854, but in the West it called Wilson's Disease. In Russia…VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies
Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…Progression of cortical thinning and neuropsychological decline in isolated Rapid Eye Movement sleep behavior disorder
Objective: We aimed to investigate the progression over time of cortical thickness and cognitive functions in isolated REM-sleep behaviour disorder (IRBD) compared to healthy controls (HC).…Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson’s disease
Objective: Parkinson's disease (PD) affects around 2-3% population of age greater than 65 and is the second most common neurogenerative disorder. The molecular mechanism underpinning…Validation of MDS-UPDRS-based score to predict conversion to freezing of gait in Parkinson’s disease
Objective: To validate an MDS-UPDRS component score for predicting conversion to freezing of gait in Parkinson’s disease. Background: Freezing of gait (FOG) is a debilitating…Treatment of hemichorea-hemiballism with valbenazine
Objective: To describe a video-case report of hemichorea-hemiballism improved by valbenazine therapy Background: Hemichorea-hemiballism (HCHB) is an uncommon movement disorder with numerous etiologies including structural…Real-World Healthcare Resource Utilization in Patients with Parkinson’s Disease and Motor Fluctuations
Objective: To evaluate healthcare resource utilization (HCRU) patterns in patients with Parkinson’s disease (PD) and motor fluctuations (MF) with carbidopa/levodopa (CD/LD) and other adjunctive PD…Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with Parkinson’s Disease
Objective: To analyze the rate of palliative care consultations among hospitalized patients with Parkinson’s Disease (PD) using the National Inpatient Sample data from 2007 to…Discrimination of alpha-synuclein strains and sub-strains in Synucleinopathies
Objective: To differentiate and characterize alpha-synuclein strains and sub-strains associated with synucleinopathies. Background: Synucleinopathies are a diverse group of neurodegenerative diseases characterized by misfolding aggregation…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »